The company has filed a patent on its StemVacs dendritic cell therapy for boosting COVID-19 immunity, it said. The patent describes how StemVacs prompts the body to boost activity of "natural killer" immunological cells, which have been shown to inhibit SARS-CoV-2.
StemVacs is being developed both as standalone immunotherapy as well as an adjuvant product to improve the efficacy of stimulators of the adaptive immune responses, according to Therapeutic Solutions. The ability to supercharge dendritic cells provides a unique virology approach to fighting COVID-19.
Copyright © 2020 scienceboard.net